Who
Victor Sandor
Director
Company insider
Files Form 4 as: Director, AbCellera Biologics; Director, Kymera Therapeutics; Director, Prelude Therapeutics; Director, ADC Therapeutics SA; Director, Merus; Chief Medical Officer, Array Biopharma.
In numbers
- Trades disclosed
- 122
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $14.6M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 1 Mar 2015
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 6 Jul 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,207 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,207 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —13,193 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,844 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —14,414 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —16,604 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —6,120 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,631 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —17,000 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,285 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $45K12,600 at $3.58 | filing |
News
Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)ADCT · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Victor Sandor; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.